Pharmaceutical compositions and the treatment of overactive bladder
The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of mictruitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.
1. A method of treating overactive bladder in a subject in need thereof, comprising administering a therapeutically effective amount of solabegron or a pharmaceutically-acceptable salt, pharmaceutically-acceptable derivative or zwitterion thereof, wherein treating overactive bladder is measured by an increase in voided volume.
2. The method of claim 1 , wherein the solabegron is in a pharmaceutical composition comprising one or more pharmaceutically-acceptable carriers, diluents, or excipients.
3. The method of claim 1 wherein the pharmaceutically-acceptable salt is the hydrochloride salt.
4. The method of claim 1 , wherein the solabegron is a zwitterion.
5. The method of claim 1 wherein the therapeutically effective amount of solabegron is between about 50 mg and about 800 mg.
6. The method of claim 1 , further comprising alleviating one or more of the symptoms of overactive bladder selected from the group consisting of urinary urgency, frequency of mictruitions, nocturia, and urgency urinary incontinence, or a combination thereof.
7. A method of treating overactive bladder in a subject in need thereof, comprising administering a therapeutically effective amount of solabegron or a pharmaceutically-acceptable salt, pharmaceutically-acceptable derivative, or zwitterion thereof, wherein the voided volume of the subject is increased.
8. The method of claim 7 , wherein the solabegron is in a pharmaceutical composition comprising one or more pharmaceutically-acceptable carriers, diluents, or excipients.
9. The method of claim 7 , wherein the pharmaceutically-acceptable salt is the hydrochloride salt.
10. The method of claim 7 , wherein the solabegron is a zwitterion.
11. The method of claim 7 , wherein the therapeutically effective amount of solabegron is between about 50 mg and about 800 mg.
12. The method of claim 7 , further comprising alleviating one or more of the symptoms of overactive bladder selected from the group consisting of urinary urgency, frequency of mictruitions, nocturia, and urgency urinary incontinence, or a combination thereof.
13. A method of treating overactive bladder in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of solabegron or a pharmaceutically-acceptable salt, pharmaceutically-acceptable derivative, or zwitterion thereof; and a therapeutically effective amount, or a sub-therapeutically effective amount, of a muscarinic receptor antagonist or a pharmaceutically-acceptable salt, or pharmaceutically-acceptable derivative thereof, wherein treating overactive bladder is measured by an increase in voided volume.
14. The method of claim 13 , wherein the solabegron is in a pharmaceutical composition comprising one or more pharmaceutically-acceptable carriers, diluents, or excipients.
15. The method of claim 13 , wherein the muscarinic receptor antagonist is in a pharmaceutical composition comprising one or more pharmaceutically-acceptable carriers, diluents, or excipients.
16. The method of claim 13 , wherein the muscarinic receptor antagonist is selected from a group consisting of oxybutynin, tolterodine, solifenacin, trospium, darifenacin, festerodine, hyoscyamine, and propiverine.
17. The method of claim 13 , wherein the muscarinic receptor antagonist is oxybutynin.
18. The method of claim 13 , wherein the solabegron is a hydrochloride salt.
19. The method of claim 13 , wherein the solabegron is a zwitterion.
20. The method of claim 13 , wherein the therapeutically effective amount of solabegron is about 50 mg to about 800 mg.
21. The method of claim 13 , wherein the therapeutically effective amount of the muscarinic receptor antagonist is about 1 mg to about 90 mg.
22. The method of claim 13 , wherein the sub-therapeutically effective amount of the muscarinic receptor antagonist is about 0.1 mg to about 50 mg.
23. The method of claim 13 , wherein the solabegron and the muscarinic receptor antagonist are co-administered.
24. The method of claim 13 , wherein the solabegron and the muscarinic receptor antagonist are contained in a single dosage form, wherein the single dosage form is a pharmaceutical composition.
25. The method of claim 13 , wherein the solabegron and the muscarinic receptor antagonist are administered separately.
26. The method of claim 13 , wherein there is a time delay between the administration of the solabegron and the muscarinic receptor antagonist.
27. The method of claim 13 , further comprising alleviating one or more of the symptoms of overactive bladder selected from the group consisting of urinary urgency, frequency of mictruitions, nocturia, and urgency urinary incontinence, or a combination thereof.
28. A method of treating overactive bladder in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of solabegron or a pharmaceutically-acceptable salt, pharmaceutically-acceptable derivative, or zwitterion thereof, and a therapeutically effective amount, or a sub-therapeutically effective amount, of a muscarinic receptor antagonist or a pharmaceutically-acceptable salt thereof, wherein the voided volume of the subject is increased.
29. The method of claim 28 , wherein the solabegron is in a pharmaceutical composition comprising one or more pharmaceutically-acceptable carriers, diluents, or excipients.
30. The method of claim 28 , wherein the muscarinic receptor antagonist is in a pharmaceutical composition comprising one or more pharmaceutically-acceptable carriers, diluents, or excipients.
31. The method of claim 28 , wherein the muscarinic receptor antagonist is selected from a group consisting of oxybutynin, tolterodine, solifenacin, trospium, darifenacin, festerodine, hyoscyamine, and propiverine.
32. The method of claim 28 , wherein the muscarinic receptor antagonist is oxybutynin.
33. The method of claim 28 , wherein the solabegron is a hydrochloride salt.
34. The method of claim 28 , wherein the solabegron is a zwitterion.
35. The method of claim 28 , wherein the therapeutically effective amount of solabegron is about 50 mg to about 800 mg.
36. The method of claim 28 , wherein the therapeutically effective amount of the muscarinic receptor antagonist is about 1 mg to about 90 mg.
37. The method of claim 28 , wherein the sub-therapeutically effective amount of the muscarinic receptor antagonist is about 0.1 mg to about 50 mg.
38. The method of claim 28 , wherein the solabegron and the muscarinic receptor antagonist are co-administered.
39. The method of claim 28 , wherein the solabegron and the muscarinic receptor antagonist are contained in a single dosage form, wherein the single dosage form is a pharmaceutical composition.
40. The method of claim 28 , wherein the solabegron and the muscarinic receptor antagonist are administered separately.
41. The method of claim 28 , wherein there is a time delay between the administration of the solabegron and the muscarinic receptor antagonist.
42. The method of claim 28 , further comprising alleviating one or more of the symptoms of overactive bladder selected from the group consisting of urinary urgency, frequency of mictruitions, nocturia, and urgency urinary incontinence, or a combination thereof.